Home > Healthcare > Analytical Instruments > Molecular Analysis > large molecule bioanalytical technologies market
Get a free sample of Large Molecule Bioanalytical Technologies Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Large Molecule Bioanalytical Technologies Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The large molecule bioanalytical technologies industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Charles River Laboratories International, Inc, Halo Labs Inc., Danaher Corporation among others have a notable presence in the market.
Some of the eminent market participants operating in the large molecule bioanalytical technologies industry include:
Some of the top industry players are Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cergentis B.V., Danaher Corporation, Halo Labs, Inc, Intertek Group plc, Laboratory Corporation of America Holdings,Shizmandu Corporation, and SOLVIAS AG.
The chromatography segment accounted for USD 2.1 billion in revenue in 2023, due to its increasing use to provides high-resolution separation of complex mixtures of large biomolecules.
North America market generated USD 3.4 billion in revenue in 2023, attributed the presence of a robust infrastructure for technology development across the region.
The market size of large molecule bioanalytical technologies reached USD 8.3 billion in revenue in 2023 and is set to surpass USD 19.9 billion by 2032, owing to the growing prevalence of chronic diseases globally.